Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
- May 15, 2026
- Posted by: Neeraj Pandey
- Category: News
Alivus Life Sciences Q4 results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT estimated approximately Rs 104 crore (Q4 FY25 PAT was Rs 141.86 crore; earnings call scheduled for May 15, 2026 at 3:00 PM IST). Life sciences company providing CDMO and pharmaceutical manufacturing services. The company declared results on May 14, 2026 and full data will be available after the earnings call. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Alivus Life Sciences Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| PAT (Net Profit) | Rs 104 crore | Q4 FY26 est. (Q4 FY25 PAT was Rs 141.86 crore; earnings call May 15, 2026) |
| Revenue from Operations | Rs 300 crore | Q4 FY26 |
| Ticker | ALIVUS | Sector: Pharma API and CDMO – Formerly Glenmark Life Sciences |
Screen the best stocks on the Univest Screener.
Alivus Life Sciences Performance Analysis
The company results reflect the company’s operational performance during the January to March 2026 quarter. Alivus Life Sciences (formerly Glenmark Life Sciences) Q4 FY26 and FY26 audited results announced May 14, 2026, with investor earnings call on May 15, 2026 at 8:30 AM IST. The company is a significant Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.
The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.
Alivus Life Sciences FY27 Outlook
Post Alivus, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharma API and CDMO – Formerly Glenmark Life Sciences space. The Alivus results demonstrate the company’s execution capabilities. Track Alivus updates on the Univest Screener for analyst views and FY27 earnings estimates.
Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.
Frequently Asked Questions on Alivus Life Sciences Q4 FY26 Results
What is Alivus Life Sciences Q4 FY26 PAT?
Ans. Alivus Life Sciences Q4 FY26 PAT of Rs 104 crore (results declared May 14, 2026). Q4 FY26 PAT estimated approximately Rs 104 crore (Q4 FY25 PAT was Rs 141.86 crore; earnings call scheduled for May 15, 2026 at 3:00 PM IST). Life scie.
When did Alivus Life Sciences announce Q4 FY26 results?
Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.
What is the FY27 outlook for Alivus Life Sciences?
Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharma API and CDMO – Formerly Glenmark Life Sciences sector. Track live updates on the Univest Screener.
Where can I track Alivus Life Sciences Q4 FY26 live data?
Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
